Business
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL HEALTH FRANCHISE Paris, February 9, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors. Masivet® is a targeted
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS","length":154,"tagName":"p"},{"type":"text","content":"AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL HEALTH FRANCHISE","length":62,"tagName":"p"},{"type":"text","content":"Paris, February 9, 2026, 6pm CET","length":32,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors.","length":212,"tagName":"p"},{"type":"text","content":"Masivet® is a targeted therapy that inhibits the juxtamembrane mutations of c-kit, which is the main driver of dog mast cell tumors.","length":132,"tagName":"p"},{"type":"text","content":"The MUMS designation is similar to the status of “Orphan Drug” for human drugs. This makes the sponsor eligible for incentives to support the approval of the designated use. When a drug is designated for a particular intended use, the sponsor of the drug obtains seven years of exclusive marketing rights upon approval of the drug for the intended use (i.e., canine mast cell tumors). A sponsor of designated new animal drugs is also eligible to apply for grants to defray the cost of studies to support the approval of the designated intended use.","length":548,"tagName":"p"},{"type":"text","content":"Masivet® is registered and commercialized in Europe and is profitable, but it is not yet registered in the USA.","length":111,"tagName":"p"},{"type":"text","content":"“The MUMS status delivered by FDA is an encouragement to develop Masivet® in the USA” states Alain Moussy, CEO of AB Science.","length":125,"tagName"...